The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario
Table 2
Overall and age-stratified PAH drug therapy utilization patterns in Ontario between April 1, 2011, and March 31, 2012.
PAH drug therapy
Overall
Age < 65
Age ≥ 65
value Age < 65 versus age ≥ 65
(%)
(%)
(%)
Overall single therapy
232 (77.1%)
118 (77.6%)
114 (76.5%)
0.817
Overall combination therapy
69 (22.9%)
34 (22.4%)
35 (23.5%)
0.817
Types of single therapy
PDE5 inhibitors
66 (28.4%)
23–28 (19–24%)
40–45 (35–39%)
0.013
ERA
140 (60.3%)
65–70 (55–59%)
70–75 (61–66%)
0.389
Prostanoids
26 (11.2%)
21–26 (20–22%)
≤5 (0–4%)
<0.001
Types of combination therapy
PDE5 inhibitors + ERA
62 (89.9%)
28–33 (82–97%)
29–34 (83–97%)
0.661
Ranges provided for privacy reasons to avoid reidentification of small cell sizes. Note: 25 out of 326 patients did not have a subsequent PAH prescription over the follow-up period, despite having a past PAH prescription, and therefore are excluded from this analysis.
